TY - JOUR AU - Swagat Tripathy AU - P. N. Murthy PY - 2018/02/13 Y2 - 2024/03/28 TI - IMPORTANCE OF DEFICIENCY RESPONSE IN PHARMACEUTICAL ENVIRONMENT FOR DRUG APPROVAL JF - International Journal of Drug Regulatory Affairs JA - Int J Drug Reg Affairs VL - 2 IS - 4 SE - Case Study DO - 10.22270/ijdra.v2i4.148 UR - https://ijdra.com/index.php/journal/article/view/148 AB - This illustrates examples of series deficiencies, that’s how really company faces problem due to deficiency. It’s to convey the message if drug product manufacturer can visualize earlier all aspect of risks and manifest proactively, then there is always least chance to have the said deficiency received. However, even then if company also gets deficiency, company could have equipped with earlier data. So, what they need to do is to focus properly for addressing agency’s query by utilizing proper scientific and technical writing skills. How lack of visualization creates problem, how review cycle prolonged and how by dint of this issue approval got delayed has been clearly discussed in this case study. The reason of so many rounds of questions and review cycles become longer and finally approval got delayed is from the beginning itself agency was not satisfied or convinced with the justification given by said Company. ER -